Vivesto AB (STO:VIVE)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.2295
-0.0010 (-0.43%)
Jun 19, 2025, 5:29 PM CET
-20.31%
Market Cap 123.48M
Revenue (ttm) n/a
Net Income (ttm) -39.62M
Shares Out 538.04M
EPS (ttm) -0.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 155,496
Average Volume 430,425
Open 0.2280
Previous Close 0.2305
Day's Range 0.2260 - 0.2300
52-Week Range 0.1992 - 0.4000
Beta 1.07
RSI 48.44
Earnings Date Aug 12, 2025

About Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company’s products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encaps... [Read more]

Sector Healthcare
Founded 1988
Employees 4
Stock Exchange Nasdaq Stockholm
Ticker Symbol VIVE
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.